Extend Biosciences, Inc.

Saladax Biomedical Inc.

Beth Israel Deaconess Medical Center, Inc.

The Beth Israel Hospital Association

Other

Galenea Corp.

Salimetrics, LLC

Galenea Pharmaceuticals

Howard Paul Sard

Vishnumurthy Hegde

Tarik Soliman

Laura M Hales

Salvatore Joseph Salamone

Jodi Blake Courtney

Daniel B Hall

Christopher So

Raj Kumar Razdan

Peter C Meltzer

Richard J Sharpe

Kenneth A Arndt

Stephen J Galli

Alexander Volkov

Christopher J Spedaliere

Mukkanti Amere

Liang Xin Xu

Louis Shuster

Bryan Roth

Cynthia Morency

Daniel J Cline

Govindaraj Kumaran

Tarik M Soliman

Geraldine C Harriman

Amy M Elder

Silvana Leit

Jon Eric Peterson

Jie Li

Yiliang Zhang

Daming Li

Doug Wilson

Xiuwen Liu

Meng-Yun Sandy Chou

Stephen L Galli

The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.

Therapeutic vitamin D conjugates

The invention provides a parathyroid hormone (PTH) compound comprising a PTH peptide. The PTH compound has a significantly increased bioavailability or circulating half-life when compared to a bioavailability or a circulating half-life of a native form of the PTH peptide. The PTH compound has a significantly greater serum concentration at multiple timepoints post-administration to a rat when compared to that of a native PTH peptide.

Therapeutic vitamin d conjugates

The invention provides monoclonal antibodies and fragments thereof that specifically bind to melatonin. Also provided are heavy chain variable region (VH) and light chain variable region (VL) sequences of such monoclonal antibodies and fragments thereof. Further provided are melatonin conjugates, and methods and uses, for example, determining, detecting, measuring, screening for, analyzing and monitoring an amount of melatonin in a sample.

Melatonin monoclonal antibody, detection, methods and uses thereof

The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.

Insulin vitamin D conjugates

The invention provides non-hormonal vitamin D conjugated via the third carbon on the vitamin D backbone to parathyroid hormone (PTH) proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms.

The invention provides carriers that enhance the absorption, half-life or bioavailability of therapeutic compounds. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties.

Carriers for improved drug delivery

The invention provides non-hormonal vitamin D conjugated to therapeutic RNA compounds that result in the compounds having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the therapeutic RNA compounds via the third carbon on the vitamin D backbone.

RNAi vitamin D conjugates

The invention provides carriers that enhance the absorption, half-life or bioavailability of Ghrelin peptides. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties.

Vitamin D-ghrelin conjugates

The present invention comprises novel conjugates and immunogens derived from gemcitabine and unique antibodies generated by using gemcitabine linked immunogens, which conjugates immunogens and antibodies, are useful in immunoassays for the quantification and monitoring of gemcitabine in biological fluids.

Gemcitabine immunoassay

Indole compounds are disclosed. Also disclosed are methods for using the compounds to treat human and animal disease, pharmaceutical compositions of the compounds, and kits including the compounds.

Compounds and methods of use thereof

Novel conjugates and immunogens derived from clozapine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of clozapine in biological fluids.

Clozapine immunoassay

Growing community of inventors

Arlington, MA, United States of America

Howard Paul Sard